Aligos Therapeutics Faces Mounting Investor Concerns After Earnings Report

Shares of Aligos Therapeutics Inc continued their downward trajectory following the release of disappointing quarterly results. The stock declined 3.49% to $9.52, though the underlying issues extend far beyond this single-day movement.

The company’s third quarter 2025 performance revealed a troubling financial picture. While Aligos surprised markets with revenue of $0.74 million, exceeding the $0.50 million expectation, this positive development was completely overshadowed by substantial earnings misses.

The core concern for investors emerged from the earnings per share figure, which came in at -$3.04 compared to analyst projections of -$2.09. This nearly one-dollar variance highlights the significant capital requirements of the company’s research and development programs.

Key Financial Metrics:

• Current Read more...